MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Therapeutic Benefits of Music for Three Types of Neurological Disorders: an fNIRS Study Protocol for Controlled Trial in Dalian, China, Part 1-Parkinson’s Disease

    LL. Pu, Z.H Liang, W.C Tang, F.Y Cong, B.W Zhang, N.K Qureshi, J. Ly, T. Li (Dalian, China)

    Objective: It is investigated that the external auditory stimuli affect motor synchronization and control in patients with PD,and further studied that how music therapy or other…
  • MDS Virtual Congress 2020

    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)

    E. Rawner, J. Powell, S. Minami, K. Tang, V. Klutzaritz, E. McCaskill Newman, J. Hannestad (San Carlos, CA, USA)

    Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
  • MDS Virtual Congress 2020

    Perspectives on care for late stage Parkinson’s disease

    K. Rosqvist, M. Kylberg, C. Löfqvist, A. Schrag, P. Odin, S. Iwarsson (Lund, Sweden)

    Objective: The aim of this study was to explore experiences of late stage Parkinson's disease (PD) patients' and their informal caregivers’ satisfaction with care and support,…
  • MDS Virtual Congress 2020

    Are effects of Rock Steady Boxing and PD SAFExTM on the motor symptoms of Parkinson’s disease maintained long-term? – A single-blinded randomized controlled trial

    K. Sangarapillai, B. Norman, Q. Almeida (Waterloo, ON, Canada)

    Objective: To determine if the benefits associated with RSB and PD SAFExTM on the motor symptoms of PD wash out over time. Background: Parkinson’s disease…
  • MDS Virtual Congress 2020

    Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease

    M. Schiess, J. Suescun, M. Doursout, C. Adams, C. Green, J. Saltarrelli, S. Savitz, T. Ellmore (Houston, TX, USA)

    Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…
  • MDS Virtual Congress 2020

    Directional versus Omnidirectional Deep Brain Stimulation: Results of a Multicenter Prospective Blinded Crossover Study

    A. Schnitzler, P. Mir, M.A Brodsky, L. Verhagen, S. Groppa, R. Alvarez, A. Evans, M. Blazquez, S. Nagel, W. Libionka, J. Pilitsis, M. Pötter-Nerger, W. Tse, L. Almeida, N. Tomycz, J. Jimenez-Shahed, F. Carrillo, C.J Hartmann, S.J Groiss, F. Defresne, E. Karst, B. Cheeran, J. Vesper (Plano, TX, USA)

    Objective: To compare the range of stimulation amplitudes that can relieve symptoms without side effects, between directional and omnidirectional DBS. Background: Published reports on directional…
  • MDS Virtual Congress 2020

    Comparison of gait measures in a clinic and a community setting in people with and without Parkinson’s disease

    V. Shah, J. McNames, M. Mancini, P. Carlson-Kuhta, J. Nutt, M. El Gohary, C. Curtze, F. Horak (Portland, OR, USA)

    Objective: This study aimed to investigate measures that best discriminated gait characteristics of people with Parkinson's disease (PD) from age-matched healthy control subjects (HC) in…
  • MDS Virtual Congress 2020

    Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease

    B.o Shen (Nanjing, China)

    Objective: To collect spatiotemporal parameter information of motor symptoms in patients with Parkinson's disease (PD) using wearable device, and analyze its correlation with the Unified…
  • MDS Virtual Congress 2020

    Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease

    J. Shirvan (Cambridge, MA, USA)

    Objective: We will present the preclinical efficacy and safety data and the design of the first in human trial of an antisense oligonucleotide (ASO) for…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains

    M. Siddiqui, V. Evidente, P. Bhargava, B. Navia, E. Pappert (Winston-Salem, NC, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…
  • « Previous Page
  • 1
  • …
  • 1129
  • 1130
  • 1131
  • 1132
  • 1133
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley